molecul larg molecul rna-bas dna-bas cell therapi focu oncolog
neurosci ophthalmolog highlight separ attach updat
model show higher estim extend increas
price target key higher estim
tcb t-cell engag bispecif tcb two bind domain give
higher affin potenc malign cell earli clinic data
r/r dlbcl patient show cr rate immedi use patient post g/
r-chop enabl high affin tcb outcompet anti-
mab target bind still effect patient residu antibodi
system despit progress ph monotherapi develop continu alongsid
ph ib combin trial tecentriq gazyva tecentriq combin intend
prevent cell exhaust activ bispecif earli clinic data
reveal deep r/r dlbcl respons gazyva combin meant attack via
two differ immun mechan tcb directli engag cell enhanc
fc region gazyva engag antibody-depend cellular cytotox adcc
avail need bound tcb order initi cell-medi target
kill make molecul potenti complimentari posit rel gred
tcb mosunetuzumab unclear gred molecul one
bind site therefor differ pharmacolog profil
bispecif fap-target bispecif intend enrich fap-
express tumor stromal cell wherein activ co-stimulatori molecul
tumor-infiltr cell reliev immunosuppress singl agent activ
observ earli ph clinic trial thymic carcinoma monotherapi combo trial
tecentriq chemo solid tumor tcb underway manag view
comparison tgf-target program necessarili appropri
mab modifi fc enhanc adcc inhibit
regulatori treg effector teff cell immune-medi deplet higher
teff treg ratio associ better clinic outcom nsclc
cancer pharmacolog increas ratio could therefor therapeut
fap fusion fusion antibodi target deliveri fap
express cell tumor microenviron variant low affin
bia activ toward activ teff cell ph monotherapi on-going well
ph ib combin cetuximab cancer ph ii combin tecentrig
 cervic esophag cancer keytruda melanoma also underway earli
clinic data promis preclin primari goal
molecul expand checkpoint inhibitor efficaci
oncolog highlight idasanutlin inhibitor ph r/r aml mirro
data cibisatamab tcb could first effect tcb solid tumor novel
protein degrad partner target radiotherapeut partner
oranom cell therapi partner sqz biotech earli develop
pleas see page report import disclosur
promis new product provid opportun upsid ep estim could fuel pe
multipl expans biosimilar risk key franchis believ adequ
reflect model long histori innov reason valuat
strengthen invest case
ocrevu multipl sclerosi hemlibra
kadcyla filings/approv adjuv
forecast
ocrevu hemlibra exceed
io portfolio gener good efficaci
biosimilar delay modest
biosimilar becom greater
price pressur diagnost re-
roch hold ag swiss pharmaceut diagnost hold compani belong
roch group oper subsidiari associ compani around
world compani two divis pharmaceut diagnost diagnost includ
four busi area diabet molecular diagnost tissu diagnosi profession
prasinezumab anti-alpha synuclein mab target solubl insolubl form
neurotox aggregate-form protein could diseas modifi parkinson pd
primari interest add-on symptomat treatment dopamin replac
ph ii part double-blind placebo-control data pasadena avail
digit biomark employ well novel skin biopsi test roche-
ventana assess potenti synucleinopathi valid test on-going
could aid earli pd diagnosi track therapeut effect
brain-shuttl gantenerumab molecul fuse roch anti-amyloid mab brain
shuttl adaptor enhanc blood-brain barrier penetr via activ transferrin
receptor-medi cell cross enhanc rapid penetr brain parenchyma
improv gantenerumab target engag potenti increas efficaci
and/or therapeut index howev manag outlin specif
hypothes test specul potenti effect amyloid-rel
imag abnorm aria repres dose-limit toxic mechanist
aria would like mediat peripher immun effect brain shuttl
technolog substanti improv therapeut window specul brain-
shuttl gantenerumab ph safeti test stand-alone molecul gantenerumab
ph earli ad guardian regard anti-amyloid approach broadli
roch drew encourag recent chang outlook biib aducanumab
risdiplam splice modifi met primari endpoint chang vs placebo
score power show differ type sma patient
year old sunfish sunfish present sma europ feb
neurosci highlight balovaptan vasopressin receptor antagonist ph
adult asd ph ii pediatr data expect htt-aso ph hd
recruit quickli basmisanil gabaa nam ph ii data schizophrenia expect
digit biomark explor across indic
formul ranibizumab lucenti anti-vegf fab show median time first refil
month ph ii ladder namd data ph archway namd refil
expect exploratori mechan pair pd
faricimab bispecif could first class ophthalmolog
inhibit could reduc inflamm improv durabl effect ph ii boulevard
show letter gain lucenti bcva week ph enrol on-going
dme namd addit indic explor
pds-dutafab dutafab novel bispecif antibodi fragment fab lower
molecular weight rel full size bispecif thu better compat pd
refil rate longer target dutafab undisclos target
preclin test clinic
plasma healthi volunt could potenti risk genet
link altern complement pathway
aav-bas gene therapi partnership deliv
intravitr aim improv whole retina transduct treatment
choroideremia transgen cargo undisclos ph initi roch
encourag approv spark luxturna first gene therapi ophthalmolog
updat model post better-than-expect sale result sale ep
forecast rais year establish
project sale rais ep
increas newli establish estim look sale
ep impli sale ep growth vs
look margin improv
compani data cowen compani estim
nettot salesgrosssg ar dop financialpretaxtaxnetepsy/yshareschf mm chg marginchf mm slschf mm slsmarginincomemarginrateinc dilut ep basi calcul ep growth post elimin exchang loss cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
point lc ex central point central point fgn lc ex central point central point diabet lc ex diabet diabet fgn lc ex diabet diabet molecular diagnost lc ex molecular diagnost molecular diagnost fgn lc ex molecular diagnost molecular diagnost tissu diagnost lc ex tissu diagnost tissu diagnost fgn lc ex tissu diagnost tissu diagnost total cowen
compani data cowen compani
 lc ex fx launch approv launch expect other phase europ lc ex fx expect approv approv japan lc ex fx advanc nsclc ovarian relaps glioblastoma breast eu ovarian cervicalmabthera/rituxan lc ex fx expir biosimilar celltrion/teva approv launch expect europ lc ex fx expir biosimilar nv celltrion/teva launch mabion/mylan file japan lc ex fx non-hodgkin lymphoma chronic lymphocyt leukemia rheumatoid arthriti pemphigu vulgari sq blunt erosionherceptin lc ex fx launch launch expect late appv celltrion/teva appv samsung bioepsis/mrk appv appv sq version approv europ lc ex fx approved/launch samsung/mrk celltrion/teva mylan/biocon japan lc ex fx breast cancer gastric sq launch countri averag share perjeta lc ex fx adjuv bc key driver sq fdc herceptin file europ lc ex fx japan lc ex fx metastat breast cancer metastat line metastat metastatickadcyla lc ex fx studi fuel growth approv europ lc ex fx file japan lc ex fx metastat bc line cowen
compani data cowen compani
 lc ex fx posit melanoma patient europ lc ex fx posit melanoma patient japan lc ex fx right pay roch royalti new zealand australia brazil india israelzelboraf inhibitor malign melanoma adjuv phase iiierivedg lc ex fx europ lc ex fx japan lc ex fx japan mexico israel south korea file australia canadaerivedg inhib fda approv advanc advanc bc aml phase ii lc ex fx europ lc ex fx expir japan lc ex fx hepat interferon-fre regimen shorter durat pressur salestarceva lc ex fx expir europ lc ex fx expir japan lc ex fx non-smal cell lung cancer pancreat canceractemra lc ex fx expir freseniu mycenax bioxpress bio-thera develop biosimilar europ lc ex fx expir japan lc ex fx ra giant cell arter crscellcept lc ex fx expir oral form iv suspens patent expir europ lc ex fx expir japan lc ex fx mofetil transplant cowen
compani data cowen compani
 lc ex fx expir europ lc ex fx expir japan lc ex fx japan lc ex fx expir gener europ lc ex fx expir japan lc ex fx treatment prevent influenza bxolair lc ex fx nasal polyp file food allergi xolair sever asthma chronic idiopath urticarialucenti lc ex fx rvo dme diabet retinopathi ncnv growth expect dme rvo ncnv pre-filled syring pd filinglucenti patent expir competit marketmircera lc ex fx launch galecia acquir right roch earn royalti europ lc ex fx japan lc ex fx expir lc ex fx europ lc ex fx japan lc ex fx beta anemia cowen
compani data cowen compani
 lc ex fx europ lc ex fx japan lc ex fx expir lc ex fx europ lc ex fx europ japan lc ex fx japan expir lc ex fx expir europ lc ex fx expir japan lc ex fx colorect breast stomach cancerboniva lc ex fx expir fgn lc ex fx lc ex fx fgn lc ex fx chugai japannutrogin/neutrogin g-csf xenic lc ex fx fgn lc ex fx lc ex fx europ lc ex fx japan lc ex fx cowen
compani data cowen compani
 lc ex fx europ lc ex fx europ japan lc ex fx japan somatropin growth hormonemadopar lc ex fx europ lc ex fx japan lc ex fx diseas patentesbriet lc ex fx europ lc ex fx japan lc ex fx japan ipf via intermun acquisit close lc ex fx nephriti file europ lc ex fx japan lc ex fx approv cll inhl mabtecentriq lc ex fx europ lc ex fx nmnm japan lc ex fx nmnm mab appv nsclc bladder cancer sclc tnbc w/chemo avastin file sq cowen
compani data cowen compani
sclerosi approv rrm ppm box warn doses/year fixa/fx biospecif mab hemophilia approv inhibitor non-inhibitior splicer sma phase nda alk-mut posit nsclc file lung approv /japan/eu posit approv r/r dlbcl r/r fl nda dlbcl nda bimab lung ntrk pantumor aprov us pend mek inhib malign melanoma combo zelboraf apprvd /eu brafm melanoma nda marboxil influenza apprd jp us healthi adults/adolesc high risk pend aml file polycythemia vera file mab neuromyel optica phase nda adnectin dmd phase in-licens nda akt inhibitor tnbc/hr bc nda neoadjuv tnbc nda ab target beta integrin subunit ulcer coliti nda diseas nda mab asthma phase ii nda cia post stroke recoveri phase ii nda bimab dme nda wet nda receptor antagonist autism phase nda mab alzheim diseas phase ii nda btk inhibitor ra lupu csu phase ii nda alpha-synuclein mab parkinson diseas phase ii nda beta antibodi alzheim phase nda first meaning data expect oncolog nda tecentriq nsclc nda huntington diseas phase ii nda potenti earlier cowen
compani data cowen compani
point lc ex fx central point point fgn lc ex fx central point point clinic chemistri coagul monitor custom biotechdiabet lc ex fx diabet fgn lc ex fx diabet glucos monitor accu-chek metersmolecular diagnost lc ex fx molecular diagnost diagnost fgn lc ex fx molecular diagnost diagnost blood screen genom sequenc pcrtissu diagnost lc ex fx tissu diagnost diagnost fgn lc ex fx tissu diagnost diagnost tissu stainingtot appli scienc integr moelcular diagnost busi cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl herceptin avastin
rituxan perjeta kadcyla actemra success pipelin product success
deal patent litig patent expir pressur biosimilar risk
success diagnost person medicin
